Skip to main content
OpenTrials

Clinical trial condition

HNSCC

Explore clinical trials studying HNSCC. Study availability and eligibility vary by location and protocol.

76 public trials 35 recruiting studies
Refine in advanced search Browse all conditions

HNSCC trial results

Recruiting

Safety and Efficacy of VB10.16 and Pembrolizumab in Patients With Head-Neck Squamous Cell Carcinoma

NCT06016920

Conditions
Carcinoma, Carcinoma, Squamous Cell, Disease Attributes, +13 more
Locations
  • CRLC Val d'Aurelle - Institut de Recherche en Cancerologie de Montpellier (IRCM) Montpellier, France
  • University of Bergen, Haukeland University Hospital Bergen, Norway
  • Oslo Universitetssykehus Oslo, Norway
  • Uniwersyteckie Cetrum Kliniczne Gdansk, Poland
View Trial Details
Recruiting

A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors

NCT07182149

Conditions
Adenocarcinoma Of Esophagus, Adnexal Diseases, Breast Diseases, +39 more
Locations
  • Normunity Investigational Site Denver, Colorado, United States
  • Normunity Investigational Site New Haven, Connecticut, United States
  • Normunity Investigational Site Minneapolis, Minnesota, United States
  • Normunity Investigational Site Maumee, Ohio, United States
View all 18 locations
View Trial Details
Recruiting

First in Human Study of TUB-030 in Patients With Advanced Solid Tumors

NCT06657222

Conditions
Advanced Solid Tumors, Breast Diseases, Breast Neoplasms, +16 more
Locations
  • Yale Cancer Center New Haven, Connecticut, United States
  • University of Miami Miami, Florida, United States
  • Dana Farber Cancer Institute Boston, Massachusetts, United States
  • Mayo Clinic Rochester, Minnesota, United States
View all 18 locations
View Trial Details
Recruiting

A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer

NCT05859074

Conditions
Adenocarcinoma, Adenocarcinoma, Sebaceous, Adnexal Carcinoma, +58 more
Locations
  • Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) Basking Ridge, New Jersey, United States
  • Memorial Sloan Kettering Monmouth (Limited protocol activities) Middletown, New Jersey, United States
  • Memorial Sloan Kettering Bergen (Limited Protocol Activities) Montvale, New Jersey, United States
  • Memorial Sloan Kettering Suffolk-Commack (Limited Protocol Activities) Commack, New York, United States
View Trial Details
Recruiting

A Study of Cemiplimab With Chemotherapy and Immunotherapy in People With Head and Neck Cancer

NCT04722523

Conditions
Carcinoma, Carcinoma, Squamous Cell, HNSCC, +11 more
Locations
  • Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) Basking Ridge, New Jersey, United States
  • Memorial Sloan Kettering Monmouth (Limited Protocol Activities) Middletown, New Jersey, United States
  • Memorial Sloan Kettering Bergen (Limited Protocol Activities) Montvale, New Jersey, United States
  • Memorial Sloan Kettering Cancer Center @ Suffolk-Commack (Consent only) Commack, New York, United States
View Trial Details
Recruiting

Objective Response Rate of Ivonescimab With Chemotherapy in Locally Advanced Resectable Oral and Oropharyngeal Squamous Cell Carcinoma

NCT07686575

Conditions
Carcinoma, Carcinoma, Squamous Cell, HNSCC, +9 more
Locations
  • Department of Stomatology, Zhujiang Hospital, Southern Medical University, Haizhu District, Guangzhou Guangzhou, Guangdong, China
  • Department of Stomatology, Zhujiang Hospital, Southern Medical University,Haizhu District Guangzhou, Guangdong, China
View Trial Details
Recruiting

A Phase I/II Trial of HCB101 in Combination With Pembrolizumab for Patients With Platinum-Refractory, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (SirH&N Trial)

NCT07136545

Conditions
Carcinoma, Carcinoma, Squamous Cell, HNSCC, +6 more
Locations
  • Chang-Gung Memorial Hospital(Lin-Kou) Taoyuan, Guishan District, Taiwan
  • National Taiwan University Hospital Taipei, Taipei City, Taiwan
  • Taipei Veterans General Hospital Taipei, Taipei City, Taiwan
View Trial Details
Recruiting

A Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCC

NCT07462377

Conditions
Bronchial Neoplasms, Carcinoma, Carcinoma, Bronchogenic, +28 more
Locations
  • START Los Angeles Los Angeles, California, United States
  • Astera Cancer Care East Brunswick, New Jersey, United States
  • START New York Long Island Lake Success, New York, United States
  • Sarah Cannon and HCA Research Institute Nashville, Tennessee, United States
View Trial Details

Related conditions